Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06248411
Status:
RECRUITING
Last Update Posted:
2024-02-21
First Post:
2023-09-26
Brief Title:
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Sponsor:
Kyowa Kirin Co Ltd
Organization:
Kyowa Kirin Co Ltd
Study Overview
Official Title:
A Phase 1 Uncontrolled Open-label Non-randomized Dose-escalation Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors Followed by an Uncontrolled Randomized Study in Patients With Esophageal Cancer or Head and Neck Squamous Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is the first in human study of KK2260 In Part 1 the maximum tolerated dose MTD will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors any cancer type Part 2 will compare the safety and tolerability of KK2260 in patients with multiple cancer types in multiple dose regimen arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None